Results 261 to 270 of about 1,511,681 (307)

Overall Survival for Osimertinib Wows

Cancer Discovery, 2023
Abstract The final overall survival (OS) results for the ADAURA trial show that osimertinib reduces the risk of death by 51% in patients with EGFR-mutated non–small cell lung cancer. For stage II or IIIA disease, the 5-year OS was 85% in patients who received osimertinib and 73% in the control group.
openaire   +2 more sources

Overall survival in older patients with cancer

BMJ Supportive & Palliative Care, 2018
ObjectivesA growing number of patients with cancer are older adults. We sought to identify the predictors for overall survival (OS) in older adults with solid tumour and haematological malignancies between January 2013 and December 2016.MethodsRetrospective cohort study.
Beatrice J Edwards, Xiaotao Zhang, Ming Sun, Juhee Song, Peter Khalil, Meghan Sri Karuturi, Linda Pang, Yunlong Geng, Colin P Dinney, Vicente Valero, Richard E Champlin, Debasish Tripathy   +11 more
openaire   +2 more sources

Overall survival in patients with metastatic melanoma

Current Medical Research and Opinion, 2015
Patients with regionally or distantly metastatic melanoma have poor long-term prognosis. The objective of this analysis was to describe survival rates among patients diagnosed with unresectable stage IIIB/C or stage IV melanoma.Using data from the Surveillance, Epidemiology, and End Results (SEER) database, patients diagnosed with unresectable stage ...
Beth Barber, Marilyn Novich, Zhongyun Zhao, Amanda M. Farr, Boris Ivanov, Xue Song   +5 more
openaire   +3 more sources

Concordance index: Surrogacy of progression-free survival for overall survival

Contemporary Clinical Trials, 2021
In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei Fan, Guosheng Yin
openaire   +2 more sources

Overall Treatment and Survival

1989
The overall pattern of gastric cancer presentation, treatment and outcome is described in this chapter. The results are described for all patients for the whole period and also by quinquennia or decades in order to evaluate changes occurring during the study period. Presentation is assessed by site and stage. The type of treatment is evaluated overall,
J. A. H. Waterhouse, William H. Allum, Jean Powell, J. W. L. Fielding, Christopher C. McConkey   +4 more
openaire   +2 more sources

2015 And Human Cancer: Back to Overall Survival

Future Oncology, 2016
10.2217/fon-2015-0085 © 2016 Future Medicine Ltd At the end of the year, it is time to take stock. What has been the revolutionary innovation in oncology in 2015? Key steps in translational research are certainly strengthening the foundations of cancer knowledge. As genome sequencing has allowed outlining the mutational landscape of several tumor types
Ciccarese C., Massari F., Tortora G.
openaire   +4 more sources